Neypomaks

• Structure
• Release form
• Pharmacological action
• Pharmacodynamics and pharmacokinetics
• Indications to use
• Contraindications
• Side effects
• Neypomaks, application instruction (Way and dosage)
• Overdose
• Interaction
• Terms of sale
• Storage conditions
• Period of validity
• Analogs
• Responses

Structure

In 1 ml of a filgrastim — 30 million. Pieces. Sodium hydroxide, polysorbate, acetic acid, sorbitol, water.

Release form

Solution in bottles for injections.

Pharmacological action

Stimulation of a leukopoiesis.

Pharmacodynamics and pharmacokinetics

Pharmacodynamics

Filgrastim is a recombinant granulotsitarny colony stimulating factor. Represents a protein from 175 amino acids. It is allocated from cells of Escherichia coli into which genetic device G-KSF of the person is entered. Has same biological activity, as well as G-KSF which is developed in a human body. Stimulates formation of neutrophils and their exit from marrow. Increase of neutrophils in blood is noted within 24 hours.

Pharmacokinetics

At any way of introduction linear dependence of concentration of active agent on a dose is noted. An elimination half-life from blood 3,5 hours. Continuous infusion of drug within 28 days does not cause cumulation, the elimination half-life also does not increase.

Indications to use

• neutropenia after chemotherapy;
• mobilization of PSKK at donors and patients;
• neutropenia after miyeloablativny treatment before transplantation of marrow;
• idiopathic or inborn neutropenia at adults and children;
• resistant neutropenia at patients with HIV infection (at inefficiency of other methods of treatment).

Contraindications

• Kostmann's syndrome of a heavy current with cytogenetic disturbances;
• hypersensitivity.

With care it is applied at a sickemia.

Side effects

• osteoporosis;
• muscle, bones, joints pains;
• diarrhea, anorexia, nausea, increase in a liver;
• leukocytosis, anemia, increase in a spleen, thrombocytopenia;
• infiltrates in lungs;
• bronkhosazm, asthma;
• fluctuations of the ABP, tachycardia;
• proteinuria and hamaturia;
• rash, face edema, small tortoiseshell;
• nasal bleeding;
• increased fatigue, weakness.

Neypomaks, application instruction (Way and dosage)

In most cases the drug is administered daily subcutaneously, in certain cases — infusionally (to dissolve only in 5% dextrose solution). The choice of a way of introduction and Neypomaks's dosage depends on a clinical situation. Schemes of treatment quite difficult, differ at different diseases and states. We bring some of them.

After a course of chemotherapy appoint 5 mkg/kg of 1 times a day p / to, daily before recovery of a normal indicator of neutrophils. The first dose is entered in a day after the termination of chemotherapy. Treatment duration about two weeks. After induction therapy of an acute myeloleukemia duration of treatment can be till 38 days. Increase in number of neutrophils is noted in 1-2 days, however for achievement of stable result it is impossible to interrupt treatment.

Miyeloablativny therapy before transplantation of marrow

Begin treatment with 10 mkg/kg a day which are entered in/in kapelno. Duration of treatment is up to 28 days.

Mobilization of PSKK at donors — 10 mkg/kg of 1 times a day, subcutaneously till 5 days with further carrying out leykaferez.

Mobilization of PSKK at the patients who studied chemotherapy — 5 mkg/kg of 1 times a day, subcutaneously, daily before normalization of values of neutrophils. Leykaferez carry out at achievement by value neutrophils> 2000/mkl.

Neutropenia at patients with HIV infection — 1-4 mkg/kg of 1 times days, subcutaneously before normalization of values of neutrophils. Then apply in a maintenance dose — 3 mkg/kg every other day.

Overdose

It is not registered.

Interaction

Not to combine reception of myelosuppressive drugs and Neypomaks in one day. At joint purpose of a 5-ftoruratsil and filgrastim strengthening of a neutropenia is noted. Lithium can strengthen effect of this drug. Pharmaceutical incompatibility from 0,9% of sodium of chloride.

Terms of sale

According to the recipe.

Storage conditions

Temperature is up to 20 °C.

Period of validity

3 years.

Neypomaks's analogs

Granogen, Neypogen, Miyelastra, Leykostim, Zarsio, Leucite.

About Neypomaks

According to responses of patients, this drug was appointed not only at the neutropenia associated with chemotherapy but also at many diseases in case of sharp decrease in quantity of neutrophils in blood are a serious autoimmune and oncological illness.

Drug is actual for patients with HIV infection, and also viral hepatitis With which accept antiviral drugs, at a juvenile pseudorheumatism. In all cases Neypomaks's use quickly was followed by increase in number of leukocytes and neutrophils — the response to stimulation comes in 9 days. However, if patients continued antiviral therapy, then and Neypomaks was accepted is long according to the scheme. Side reactions were noted.

• "… 7 months on Neypomaksa! There was a fever and joints hurt".
• "… Against reception of this drug there was fever, legs hurt very much".
• "… Transferred not bad, any reaction — neither temperature, nor an ache in bones. Only dryness in a mouth and the head heavy".

Thus, drug is quite often used and possesses high performance at treatment and prevention of a neutropenia.